MARYVILLE, Tenn. – (Sept 17, 2015) – Geneuity and Molecular Pathology Laboratory Network (MPLN) today announced that it is expanding its integrated oncology specialty testing offering to include Next Generation Sequencing assays for solid tumor. The new panels will address Lung, Colon, Melanoma and an unknown primary 8 gene panel with soon to be released Gastrointestinal Stroma, Glioma, Ovarian, Renal and Thyroid solid tumor panels. Geneuity will be making the QIAGEN Human Tumor Actionable Mutations Panel available for clinical trial studies.
Maryville, Tennessee – (July 15, 2015) – (Business Wire). Geneuity today announced that it is expanding early access to Thermo Fisher Scientific’s targeted, next generation sequencing (NGS) technology and Oncomine Focus Assay for services it plans to offer to its broad pharmaceutical customer base.